Format

Send to

Choose Destination
Sci Rep. 2014 Mar 28;4:4504. doi: 10.1038/srep04504.

Increased expression of p62/SQSTM1 in prion diseases and its association with pathogenic prion protein.

Author information

1
Department of Molecular Microbiology and immunology, Graduate School of Biomedical sciences, Nagasaki University, Nagasaki 852-8523, Japan.
2
1] Department of Molecular Microbiology and immunology, Graduate School of Biomedical sciences, Nagasaki University, Nagasaki 852-8523, Japan [2] Nagasaki University Research Centre for Genomic Instability and Carcinogenesis, Nagasaki 852-8523, Japan.

Abstract

Prion diseases are neurodegenerative disorders characterized by the aggregation of abnormally folded prion protein (PrP(Sc)). In this study, we focused on the mechanism of clearance of PrP(Sc), which remains unclear. p62 is a cytosolic protein known to mediate both the formation and degradation of aggregates of abnormal proteins. The levels of p62 protein increased in prion-infected brains and persistently infected cell cultures. Upon proteasome inhibition, p62 co-localized with PrP(Sc), forming a large aggregate in the perinuclear region, hereafter referred to as PrP(Sc)-aggresome. These aggregates were surrounded with autophagosome marker LC3 and lysosomes in prion-infected cells. Moreover, transient expression of the phosphomimic form of p62, which has enhanced ubiquitin-binding activity, reduced the amount of PrP(Sc) in prion-infected cells, indicating that the activation of p62 could accelerate the clearance of PrP(Sc). Our findings would thus suggest that p62 could be a target for the therapeutic control of prion diseases.

PMID:
24675871
PMCID:
PMC3968452
DOI:
10.1038/srep04504
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center